Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Cash & Equivalents (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Cash & Equivalents for 4 consecutive years, with $25.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 24.91% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, up 24.91% year-over-year, with the annual reading at $25.2 million for FY2025, 24.91% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $25.2 million at LENZ Therapeutics, down from $25.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $200.4 million in Q1 2024, with the low at $8.0 million in Q1 2023.
  • Average Cash & Equivalents over 4 years is $76.0 million, with a median of $47.7 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 95.7% in 2023, then skyrocketed 2416.42% in 2024.
  • Over 4 years, Cash & Equivalents stood at $47.7 million in 2022, then surged by 283.38% to $183.0 million in 2023, then tumbled by 88.98% to $20.2 million in 2024, then rose by 24.91% to $25.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $25.2 million, $25.4 million, and $37.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.